Novartis: FDA approves label update for psoriasis drug
(CercleFinance.com) - Novartis said on Thursday that the US Food and Drug Administration has approved a label update for its psoriasis drug Cosentyx, including data in moderate-to-severe scalp psoriasis - one of the more difficult-to-treat forms of the disease.
The label update, effective in the US immediately, is based on positive results from a Phase III scalp psoriasis trial.
Novartis says this type of the disease affects approximately half of all psoriasis patients.
Copyright (c) 2018 CercleFinance.com. All rights reserved.
The label update, effective in the US immediately, is based on positive results from a Phase III scalp psoriasis trial.
Novartis says this type of the disease affects approximately half of all psoriasis patients.
Copyright (c) 2018 CercleFinance.com. All rights reserved.